CBP 1039
Alternative Names: CBP-1039Latest Information Update: 12 Jul 2022
Price :
$50 *
At a glance
- Originator Coherent Biopharma (Suzhou)
- Class Antineoplastics; Drug conjugates
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Jun 2022 Preclinical trials in Solid tumours in China (Unspecified) (Coherent Biopharma pipeline; June 2022)
- 18 Jun 2022 Coherent Biopharma (Suzhou) has patent protection for Bi-Engaging Ligand Mediated Selective Targeting (BESTTM) technology in five countries before June 2021 (Coherent Biopharma (Suzhou) technology platform, June 2021)